Pricing Log in Create free account

Maze Therapeutics, Inc. (MAZE) vs Zenas BioPharma, Inc. (ZBIO)

Maze Therapeutics, Inc. and Zenas BioPharma, Inc. are both Biotechnology companies. Maze Therapeutics, Inc. and Zenas BioPharma, Inc. are of similar size ($1.8B and $1.8B). Across the 10 metrics below, Maze Therapeutics, Inc. leads on 7 and Zenas BioPharma, Inc. on 3.

Valuation

Metric MAZE ZBIO Biotechnology median
P/E n/m n/m 8.58
P/S n/m n/m 10.29
P/B 4.17 7.22 2.29
Price to free cash flow n/m n/m 21.93
EV/EBITDA n/m n/m 0.67
EV/Sales n/m n/m 9.89
Earnings yield (7.87%) (31.82%) (31.56%)
Free cash flow yield (5.66%) (12.67%) (23.42%)

Profitability

Metric MAZE ZBIO Biotechnology median
Gross margin — — 65.77%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (37.35%) (199.04%) (54.09%)
Return on assets (31.99%) (97.39%) (47.78%)
Return on invested capital (112.36%) 0.00% 0.00%

Growth

Metric MAZE ZBIO Biotechnology median
Revenue growth (TTM) — — 5.83%
EPS growth (last fiscal year) (344.00%) 29.04% 29.36%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric MAZE ZBIO Biotechnology median
Debt to equity 0.09 1.57 0.00
Current ratio 18.31 9.93 4.80
Net debt to EBITDA 2.43 0.69 0.97

Dividend

Metric MAZE ZBIO Biotechnology median
Dividend yield — — 0.44%
Payout ratio — — —

Size

Metric MAZE ZBIO Biotechnology median
Market cap 1.81b 1.83b 153.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack